Campbell & Co Investment Adviser’s Travere Therapeutics TVTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-48,191	Closed	-$1.15M	–	1417
2025 Q3	$1.15M	Buy	48,191 +31,875	+195%	+$599K	0.09%	362
2025 Q2	$241K	Buy	+16,316	New	+$270K	0.02%	1016
2022 Q1	–	Sell	-7,300	Closed	-$227K	–	914
2021 Q4	$227K	Buy	+7,300	New	+$206K	0.08%	480
2021 Q3	–	Sell	-31,000	Closed	-$452K	–	776
2021 Q2	$452K	Buy	+31,000	New	+$611K	0.19%	177
2019 Q2	–	Sell	-9,601	Closed	-$217K	–	709
2019 Q1	$217K	Buy	+9,601	New	+$212K	0.11%	410
2017 Q4	–	Sell	-10,017	Closed	-$249K	–	514
2017 Q3	$249K	Buy	+10,017	New	+$221K	0.2%	218

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Campbell & Co Investment Adviser's TVTX Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 48,191 shares — an estimated $1.15M sold.

Campbell & Co Investment Adviser first reported a position in TVTX in Q3 2017 and held it in 6 quarters. The position peaked at $1.15M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 48,191 Travere Therapeutics shares in Q4 2025, an estimated $1.15M.
Campbell & Co Investment Adviser first reported a position in Travere Therapeutics in Q3 2017 and held it in 6 quarters.
Campbell & Co Investment Adviser's Travere Therapeutics position peaked at $1.15M in Q3 2025.
278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.